Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MicroBase Technology Corp. (3184.TWO)
Taoyuan City, TW
MicroBase Technology Corp., founded in 1997 and headquartered in Taoyuan City, Taiwan, specializes in providing critical drug administration solutions to patients and medical professionals throughout Taiwan. A key area of their expertise involves pioneering the development of non-silicon-based Micro-Electro-Mechanical Systems (MEMS) by leveraging LIGA technology. This sophisticated method facilitates the engineering and production of extremely small devices and micron-sized components. Their product offerings include "Pocket Air," an innovative inhalation device designed to assist individuals with respiratory conditions, and "PharMatrix," a line of micro-needle products tailored for convenient at-home application by women.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.84% | -5.56% | +15.40% | +69.35% | +87.13% | +137.12% | +84.94% | +5.54% | +51.68% | -18.78% | -70.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Hardware, Equipment & Parts: +10.0%-1.4% Q4'25: -7.5% (vs Q4'23)
-
EPS growth Hardware, Equipment & Parts: +20.2%-44.8% Q4'25: -17.9% (vs Q4'23)
-
FCF margin FCF growth · Hardware, Equipment & Parts: +27.1%+18.2% Q4'25: +23.4% (vs Q4'23)
-
EBIT margin Hardware, Equipment & Parts: +8.7%+21.7% ★ Q4'25: +11.7% (vs Q4'23)
-
ROIC Hardware, Equipment & Parts: +5.7%+10.5% ★ Q4'25: +10.2% (vs Q4'23)
-
Share dilution Hardware, Equipment & Parts: +0.0%-21.8% ★ Q4'25: -44.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Hardware, Equipment & Parts: -0.70×0.02× ★ Q4'25: 0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 3/5 | 4/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 3/5 | 4/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-06 | A+ | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-05 | A+ | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pei Ying Hong | Accounting Supervisor | — | — |
| Tian Lai Liu | General Manager | — | — |
| Zheng Xing Gao | Deputy GM & Head of Finance Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3184.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
